Literature DB >> 24488925

The Mdm network and its regulation of p53 activities: a rheostat of cancer risk.

Christine M Eischen1, Guillermina Lozano.   

Abstract

The potent transcriptional activity of p53 (Trp53, TP53) must be kept in check for normal cell growth and survival. Tumors, which drastically deviate from these parameters, have evolved multiple mechanisms to inactivate TP53, the most prevalent of which is the emergence of TP53 missense mutations, some of which have gain-of-function activities. Another important mechanism by which tumors bypass TP53 functions is via increased levels of two TP53 inhibitors, MDM2, and MDM4. Studies in humans and in mice reveal the complexity of TP53 regulation and the exquisite sensitivity of this pathway to small changes in regulation. Here, we summarize the factors that impinge on TP53 activity and thus cell death/arrest or tumor development.
© 2014 WILEY PERIODICALS, INC.

Entities:  

Keywords:  Mdm2; Mdm4; TCGA; TP53; Trp53; mouse models; p53

Mesh:

Substances:

Year:  2014        PMID: 24488925      PMCID: PMC4725600          DOI: 10.1002/humu.22524

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  144 in total

Review 1.  Divorcing ARF and p53: an unsettled case.

Authors:  Charles J Sherr
Journal:  Nat Rev Cancer       Date:  2006-08-17       Impact factor: 60.716

2.  Multiple stress signals activate mutant p53 in vivo.

Authors:  Young-Ah Suh; Sean M Post; Ana C Elizondo-Fraire; Daniela R Maccio; James G Jackson; Adel K El-Naggar; Carolyn Van Pelt; Tamara Terzian; Guillermina Lozano
Journal:  Cancer Res       Date:  2011-10-07       Impact factor: 12.701

3.  Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome.

Authors:  G Bougeard; S Baert-Desurmont; I Tournier; S Vasseur; C Martin; L Brugieres; A Chompret; B Bressac-de Paillerets; D Stoppa-Lyonnet; C Bonaiti-Pellie; T Frebourg
Journal:  J Med Genet       Date:  2005-10-28       Impact factor: 6.318

4.  Amplification of a gene encoding a p53-associated protein in human sarcomas.

Authors:  J D Oliner; K W Kinzler; P S Meltzer; D L George; B Vogelstein
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

5.  ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways.

Authors:  Y Zhang; Y Xiong; W G Yarbrough
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

6.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.

Authors:  S N Jones; A E Roe; L A Donehower; A Bradley
Journal:  Nature       Date:  1995-11-09       Impact factor: 49.962

7.  Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation.

Authors:  S Venkatachalam; Y P Shi; S N Jones; H Vogel; A Bradley; D Pinkel; L A Donehower
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

8.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.

Authors:  Y Cho; S Gorina; P D Jeffrey; N P Pavletich
Journal:  Science       Date:  1994-07-15       Impact factor: 47.728

9.  Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2.

Authors:  T Kamijo; J D Weber; G Zambetti; F Zindy; M F Roussel; C J Sherr
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

10.  Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.

Authors:  J M Birch; V Blair; A M Kelsey; D G Evans; M Harris; K J Tricker; J M Varley
Journal:  Oncogene       Date:  1998-09-03       Impact factor: 9.867

View more
  36 in total

1.  The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis.

Authors:  Shunbin Xiong; Vinod Pant; Yun Zhang; Neeraj K Aryal; M James You; Donna Kusewitt; Guillermina Lozano
Journal:  J Pathol       Date:  2017-01-06       Impact factor: 7.996

Review 2.  Genome Stability Requires p53.

Authors:  Christine M Eischen
Journal:  Cold Spring Harb Perspect Med       Date:  2016-06-01       Impact factor: 6.915

Review 3.  Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End.

Authors:  Amanda R Wasylishen; Guillermina Lozano
Journal:  Cold Spring Harb Perspect Med       Date:  2016-08-01       Impact factor: 6.915

4.  Acetylation Is Crucial for p53-Mediated Ferroptosis and Tumor Suppression.

Authors:  Shang-Jui Wang; Dawei Li; Yang Ou; Le Jiang; Yue Chen; Yingming Zhao; Wei Gu
Journal:  Cell Rep       Date:  2016-10-04       Impact factor: 9.423

5.  Peli1 Modulates the Subcellular Localization and Activity of Mdmx.

Authors:  Dawei Li; Omid Tavana; Shao-Cong Sun; Wei Gu
Journal:  Cancer Res       Date:  2018-03-09       Impact factor: 12.701

6.  Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes.

Authors:  G J Ortiz; Y Li; S M Post; V Pant; S Xiong; C A Larsson; A K El-Naggar; D G Johnson; G Lozano
Journal:  Oncogene       Date:  2017-09-18       Impact factor: 9.867

Review 7.  Senescent cells: an emerging target for diseases of ageing.

Authors:  Bennett G Childs; Martina Gluscevic; Darren J Baker; Remi-Martin Laberge; Dan Marquess; Jamie Dananberg; Jan M van Deursen
Journal:  Nat Rev Drug Discov       Date:  2017-07-21       Impact factor: 84.694

8.  An EZH2-mediated epigenetic mechanism behind p53-dependent tissue sensitivity to DNA damage.

Authors:  Gamze Kuser-Abali; Lu Gong; Jiawei Yan; Qingqing Liu; Weiqi Zeng; Amanda Williamson; Chuan Bian Lim; Mary Ellen Molloy; John B Little; Lei Huang; Zhi-Min Yuan
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-14       Impact factor: 11.205

9.  Ubiquitin-specific protease 39 is overexpressed in human lung cancer and promotes tumor cell proliferation in vitro.

Authors:  Zhifeng Lin; Liwen Xiong; Qiang Lin
Journal:  Mol Cell Biochem       Date:  2016-09-15       Impact factor: 3.396

Review 10.  Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives.

Authors:  Darren J Baker; Ronald C Petersen
Journal:  J Clin Invest       Date:  2018-02-19       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.